Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell 4Lymphoma, Large-Cell, Anaplastic 4Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Immunoblastic Lymphadenopathy 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 28fludarabine phosphate 22Peripheral Blood Stem Cell Transplantation 22Whole-Body Irradiation 18Etoposide 17Mycophenolic Acid 14Doxorubicin 13Tacrolimus 12Vincristine 11Prednisone 11Cyclosporine 11Methotrexate 10Busulfan 10Melphalan 9Bortezomib 9Rituximab 8Antilymphocyte Serum 8Filgrastim 7Carboplatin 7Radiotherapy 6Lenalidomide 6Everolimus 6romidepsin 5Vorinostat 5Therapeutics 5etoposide phosphate 4Sirolimus 4Panobinostat 4Immunohistochemistry 4Ifosfamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Immunoblastic Lymphadenopathy × Lactones × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

M.D. Anderson Cancer Center

Phase 1 Completed
22 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡